COMPASS Pathways and COMP360 psilocybin therapy
At the end of 2021, UK-based COMPASS Pathways shared positive results from its Phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD).
The study was the largest ever conducted with the psychedelic medicine, with 233 patients included at 22 sites across Europe and North America.
The trial demonstrated that patients who received a single 25mg dose of COMPASS’s proprietary psilocybin formulation, COMP360, with psychological support, experienced a significant reduction in depressive-symptom severity after three weeks, with a rapid and sustained response lasting the 12-week duration of the trial.
To discuss the study, which COMPASS hopes will lead to COMP360 psilocybin therapy’s regulatory approval, PSYCH spoke with the company’s Chief Medical Officer, Dr Guy Goodwin.READ MORE